Table 1.
Baseline characteristics of the included AF patients
| Total population (n = 768) | Intervention groups (n = 677) | Standard care (n = 91) | p value* | |
|---|---|---|---|---|
| Male, n (%) | 535 (69.7) | 472 (69.7) | 63 (69.2) | 0.924 |
| Age (years), mean ± SD | 70.1 ± 7.9 | 70.1 ± 8.0 | 70.2 ± 7.6 | 0.992 |
| CHA2DS2-VASc score, mean ± SD | 3.2 ± 1.6 | 3.2 ± 1.5 | 3.5 ± 1.6 | 0.227 |
| HAS-BLED score, mean ± SD | 1.5 ± 0.8 | 1.5 ± 0.8 | 1.6 ± 0.9 | 0.357 |
| Time since AF diagnosis (years), mean ± SD | 5.8 ± 7.0 | 5.8 ± 7.1 | 6.1 ± 6.1 | 0.501 |
| Oral anticoagulation, n (%) | 0.457 | |||
| Apixaban | 207 (27.0) | 176 (26.0) | 31 (34.1) | |
| Edoxaban | 246 (32.0) | 223 (32.9) | 23 (25.3%) | |
| Rivaroxaban | 167 (21.7) | 148 (21.9) | 19 (20.9) | |
| Dabigatran | 69 (9.0) | 61 (9.0) | 8 (8.8) | |
| VKA | 72 (9.4) | 62 (9.2) | 10 (11.0) | |
| OAC started during the study | 7 (0.9) | 7 (1.0) | 0 (0.0) |
AF Atrial fibrillation, SD Standard DEVIATION, CHA2DS2-VASc Congestive heart failure (1), Hypertension (1), Age > 75 years (2), Diabetes mellitus (1), stroke (2), Vascular disease (1), Age 65–74 years (1), Sex category (female = 1); HAS-BLED Systolic blood pressure > 160 mmHg (1), Abnormal renal and/or hepatic function (1 point each), stroke (1), Bleeding history or predisposition (1), Labile INR (1), age > 65 years (1), Drugs or excessive alcohol drinking (1 point each); VKA Vitamin K Antagonist
*A Mann–Whitney U test was used for continuous data, and a chi-square test was used for categorical data